Total Payments
$328,478
2024 Payments
$50,397
Companies
43
Transactions
479
Medicare Patients
2,008
Medicare Billing
$2.1M
Payment Breakdown by Category
Other$230,030 (70.0%)
Consulting$47,003 (14.3%)
Travel$42,634 (13.0%)
Food & Beverage$8,561 (2.6%)
Education$249.69 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $227,820 | 72 | 69.4% |
| Consulting Fee | $47,003 | 27 | 14.3% |
| Travel and Lodging | $42,634 | 114 | 13.0% |
| Food and Beverage | $8,561 | 255 | 2.6% |
| Honoraria | $2,210 | 3 | 0.7% |
| Education | $249.69 | 8 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $115,875 | 116 | $0 (2024) |
| Myovant Sciences Inc. | $65,889 | 49 | $0 (2022) |
| Merck Sharp & Dohme LLC | $57,341 | 59 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $28,301 | 35 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $23,764 | 21 | $0 (2024) |
| Progenics Pharmaceuticals, Inc. | $16,780 | 18 | $0 (2023) |
| Eli Lilly and Company | $3,876 | 8 | $0 (2023) |
| Myriad Genetic Laboratories, Inc. | $3,842 | 14 | $0 (2022) |
| Dendreon Pharmaceuticals LLC | $1,982 | 12 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $1,947 | 17 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $50,397 | 78 | Ferring Pharmaceuticals Inc. ($23,764) |
| 2023 | $63,874 | 78 | Merck Sharp & Dohme LLC ($41,667) |
| 2022 | $156,765 | 163 | Janssen Biotech, Inc. ($76,515) |
| 2021 | $30,046 | 85 | Myovant Sciences Inc. ($18,530) |
| 2020 | $4,488 | 31 | Dendreon Pharmaceuticals LLC ($1,690) |
| 2019 | $17,033 | 15 | AstraZeneca Pharmaceuticals LP ($16,662) |
| 2018 | $5,443 | 22 | AstraZeneca Pharmaceuticals LP ($3,000) |
| 2017 | $431.39 | 7 | Photocure Inc ($356.58) |
All Payment Transactions
479 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $26.47 | General |
| Category: HORMONE THERAPY | ||||||
| 12/06/2024 | pharmaand GmbH | Rubraca (Drug) | Food and Beverage | Cash or cash equivalent | $25.23 | General |
| Category: PARP inhibitor | ||||||
| 11/22/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $28.30 | General |
| 10/25/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $28.49 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 10/18/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $27.97 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: Oncology | ||||||
| 08/30/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $26.97 | General |
| Category: HORMONE THERAPY | ||||||
| 08/28/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,470.00 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $27.85 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $33.50 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 08/08/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,470.00 | General |
| Category: ONCOLOGY | ||||||
| 08/02/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: Oncology | ||||||
| 08/02/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $3.38 | General |
| Category: Oncology | ||||||
| 07/26/2024 | Ferring Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $23.27 | General |
| 07/22/2024 | AstraZeneca Pharmaceuticals LP | Truqap (Drug) | Consulting Fee | Cash or cash equivalent | $1,330.00 | General |
| Category: Oncology | ||||||
| 07/19/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: HORMONE THERAPY | ||||||
| 07/12/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $24.26 | General |
| 07/02/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $817.50 | General |
| 06/28/2024 | Janssen Scientific Affairs, LLC | AKEEGA (Drug), ERLEADA | Food and Beverage | In-kind items and services | $29.13 | General |
| Category: Oncology | ||||||
| 06/27/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,470.00 | General |
| Category: ONCOLOGY | ||||||
| 06/21/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 06/21/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $30.47 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 06/20/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,470.00 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | Cash or cash equivalent | $15.46 | General |
| Category: Oncology | ||||||
| 06/14/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $23.30 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 132 | 182 | $35,647 | $13,246 |
| 2022 | 10 | 286 | 3,015 | $202,851 | $77,226 |
| 2021 | 17 | 655 | 3,739 | $2.7M | $2.0M |
| 2020 | 17 | 935 | 1,389 | $357,976 | $92,029 |
Total Patients
2,008
Total Services
8,325
Medicare Billing
$2.1M
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 41 | 65 | $15,145 | $5,879 | 38.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 25 | $6,150 | $3,319 | 54.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 11 | 17 | $4,777 | $1,759 | 36.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 25 | $4,125 | $1,389 | 33.7% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 35 | 50 | $5,450 | $901.00 | 16.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 11 | 2,520 | $63,000 | $42,675 | 67.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 13 | 90 | $86,760 | $12,450 | 14.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 57 | 95 | $17,474 | $8,615 | 49.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 65 | 90 | $10,950 | $5,500 | 50.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 25 | 30 | $7,380 | $4,188 | 56.7% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2022 | 62 | 101 | $11,009 | $1,839 | 16.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 15 | 15 | $3,095 | $830.10 | 26.8% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 13 | 30 | $1,740 | $801.18 | 46.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 11 | 25 | $1,025 | $286.69 | 28.0% |
| 81003 | Automated urinalysis test | Office | 2022 | 14 | 19 | $418.00 | $41.88 | 10.0% |
| Q2043 | Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion | Office | 2021 | 17 | 46 | $2.4M | $1.8M | 76.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 17 | 2,700 | $67,500 | $44,278 | 65.6% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2021 | 24 | 138 | $133,032 | $21,023 | 15.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 78 | 117 | $20,358 | $10,405 | 51.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 98 | 142 | $16,330 | $8,941 | 54.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 49 | 61 | $15,006 | $7,431 | 49.5% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 16 | 45 | $12,645 | $5,318 | 42.1% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2021 | 120 | 191 | $20,819 | $3,512 | 16.9% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Facility | 2021 | 24 | 30 | $17,040 | $1,807 | 10.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 14 | 14 | $2,814 | $1,267 | 45.0% |
About Dr. Daniel Canter, MD
Dr. Daniel Canter, MD is a Urology healthcare provider based in Decatur, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689730061.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Canter, MD has received a total of $328,478 in payments from pharmaceutical and medical device companies, with $50,397 received in 2024. These payments were reported across 479 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($227,820).
As a Medicare-enrolled provider, Canter has provided services to 2,008 Medicare beneficiaries, totaling 8,325 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Other Specialties Urology, Urology
- Location Decatur, GA
- Active Since 12/29/2006
- Last Updated 09/09/2019
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1689730061
Products in Payments
- ERLEADA (Drug) $111,290
- ORGOVYX (Drug) $64,515
- KEYTRUDA (Biological) $57,293
- ADSTILADRIN (Biological) $23,741
- PYLARIFY (Drug) $16,780
- IMFINZI (Drug) $12,429
- LYNPARZA (Drug) $7,208
- PROVENGE (Drug) $1,982
- Prolaris (Device) $1,957
- Nubeqa (Drug) $1,894
- BRACAnalysis CDx (Device) $1,522
- Truqap (Drug) $1,330
- Da Vinci Surgical System (Device) $1,310
- TALZENNA (Drug) $1,110
- CAMCEVI (Drug) $902.44
- XTANDI (Drug) $683.75
- Cysview (Drug) $672.43
- BRACANALYSIS CDX (Device) $362.58
- XIAFLEX (Biological) $133.19
- CALQUENCE (Drug) $101.39
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Decatur
Dr. Michael Kemper, M.d, M.D
Urology — Payments: $76,978
Urology $76,978
Dr. Syed Jafri, M.d, M.D
Urology — Payments: $16,394
Urology $16,394
Dr. Sergey Ananyev, M.d, M.D
Urology — Payments: $12,352
Urology $12,352
Walter Falconer, M.d, M.D
Urology — Payments: $12,271
Urology $12,271
Dr. Lambda Msezane, M.d, M.D
Urology — Payments: $11,285
Urology $11,285
William Hughes, Md, MD
Urology — Payments: $6,822
Urology $6,822